Tufts University

Cyclerion Therapeutics, Inc.

Paratek Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc.

Tisento Therapeutics Inc.

Other

Glen Robert Rennie

Mark L Nelson

Paul A Renhowe

Darrell J Koza

Rajesh R Iyengar

Takashi Nakai

Thomas Wai-Ho Lee

Joon Jung

Ara Mermerian

Timothy Claude Barden

G-Yoon Jamie Im

Karthik Iyer

James Edward Sheppeck

Nicholas Robert Perl

Mark G Currie

Xiang Y Yu

Joel D Moore

Lei Jia

Colleen Hudson

Kimberly Kafadar Long

George Todd Milne

Beena Bhatia

Laura McIntyre

James Jia

Kim Tang

Roger Frechette

David Messersmith

Mohamed Y Ismail

Todd Bowser

Tadeusz Warchol

Peter Viski

Paul Sheahan

Atul K Verma

Paul Hawkins

Peter Germano

Upul Keerthi Bandarage

Karen Stapleton

Nicholas Perl

Jimmy Dumornay

Gui Liu

Tad Warchol

Helen Cumberbatch

Paul Allen Renhowe

Laura Mcintyre

Mark Currie

Paul Allan Renhowe

Ted Warchol

Mcintyre Laura

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula I:

sGC stimulators

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts, pharmaceutical formulations comprising them as well as their phosphate ester prodrugs, and their uses alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or the upregulation of the NO pathway is desirable. The compounds are of Formula I.

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable. The compounds are of Formula I:

SGC stimulators

Compounds of Formulae I' and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed. 

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula (I). 

The present patent application discloses the compounds according to Formula (I) shown below, or pharmaceutically acceptable salts thereof wherein J, n, R, R, R, R, R, m and X as defined herein. 

Phosphorus prodrugs of pyrazolo-substituted pyrimidine sGC stimulators

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable. The compounds are of Formula I: 

The present patent application discloses at least the compounds according to Formula I' shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, ring E, J, n, J, J, X, Z, Z, R, R, Y, R, o and W are as defined herein.

The present patent application discloses at least the compounds according to Formula I' shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, ring E, ring F, J, n, J, J, o, R, R, W, J, r, J, s, Z, Zand Zare as defined herein.

Growing community of inventors

Somerville, MA, United States of America

Glen Robert Rennie